Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28240836 | 0.97 | MEN1 (0.58) | TSHRMAPK1MEN1KMT2ATHRB | |
| SCHEMBL7090333 | 0.88 | MEN1 (0.69) | TSHRMAPK1MEN1KMT2ATHRB | |
| SCHEMBL15053508 | 0.88 | MEN1 (0.69) | TSHRMAPK1MEN1KMT2ATHRB | |
| SCHEMBL14917423 | 0.88 | MEN1 (0.69) | TSHRMAPK1MEN1KMT2ATHRB | |
| SCHEMBL187893 | 0.88 | — | — | |
| SCHEMBL16353877 | 0.88 | MEN1 (0.69) | TSHRMAPK1MEN1KMT2ATHRB | |
| SCHEMBL3681429 | 0.88 | MEN1 (0.69) | TSHRMAPK1MEN1KMT2ATHRB | |
| SCHEMBL3680436 | 0.88 | MEN1 (0.69) | TSHRMAPK1MEN1KMT2ATHRB | |
| SCHEMBL190431 | 0.88 | MEN1 (0.69) | TSHRMAPK1MEN1KMT2ATHRB | |
| SCHEMBL2701918 | 0.88 | MEN1 (0.69) | TSHRMAPK1MEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | disclosed |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | disclosed |
| EP-3740493-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | disclosed |
| CN-111601810-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-08-28 | — | — | CN | disclosed |
| US-5942641-A | TREATMENT OF ALZHEIMER'S DISEASE, NERVOUS SYSTEM DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-24 | — | — | US | disclosed |
| EP-0655992-B1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMA CO LTD (JP) | 1998-11-04 | — | — | EP | disclosed |
| EP-0791570-A1 | Fluorenone derivatives, process for preparing the same and central or peripheral nerve degeneration repair and protective agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-27 | — | — | EP | disclosed |
| WO-1995000468-A1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDO2, TDO2, IDO1 | TSHR 1858/4885MAPK1 3817/4885MEN1 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.